ECM
CORT icon

Evergreen Capital Management’s Corcept Therapeutics CORT Stock Holding History

Evergreen Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$784K Sell
9,014
-252
-3% -$15.2K 0.01% 657
2026
Q1 		$374K Buy
9,266
+657
+8% +$24.6K 0.01% 980
2025
Q4 		$300K Buy
8,609
+248
+3% +$19.5K 0.01% 1038
2025
Q3 		$695K Buy
8,361
+755
+10% +$54.6K 0.02% 509
2025
Q2 		$558K Buy
7,606
+448
+6% +$32.5K 0.02% 515
2025
Q1 		$818K Buy
7,158
+265
+4% +$16.1K 0.03% 368
2024
Q4 		$347K Buy
6,893
+181
+3% +$9.48K 0.01% 663
2024
Q3 		$311K Buy
6,712
+48
+0.7% +$1.71K 0.01% 692
2024
Q2 		$217K Buy
+6,664
New +$183K 0.01% 819
2024
Q1 		– Sell
-6,651
Closed -$216K – 885
2023
Q4 		$216K Buy
+6,651
New +$183K 0.01% 746

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evergreen Capital Management's CORT Position: Q2 2026 in Review

Evergreen Capital Management reduced its Corcept Therapeutics (CORT) stake by 2.7% in Q2 2026, selling an estimated $15.2K and leaving 9,014 shares worth $784K. The position accounts for 0.01% of the portfolio, ranked #657.

Evergreen Capital Management first reported a position in CORT in Q4 2023 and has held it in 10 quarters since. The position peaked at $818K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Evergreen Capital Management held 9,014 shares of Corcept Therapeutics worth $784K as of Q2 2026.
  • Evergreen Capital Management sold 252 Corcept Therapeutics shares in Q2 2026, an estimated $15.2K.
  • Corcept Therapeutics made up 0.01% of Evergreen Capital Management's portfolio in Q2 2026, its #657 holding.
  • Evergreen Capital Management first reported a position in Corcept Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • Evergreen Capital Management's Corcept Therapeutics position peaked at $818K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Evergreen Capital Management's 13F filing for Q2 2026, filed 23 Jul 2026.